CD1C and neoplasm: In order to increase the amount of available tumor antigen and optimize the maturation potential of CD1c (BDCA-1)+ myDCs in situ, the IgG1 subtype monoclonal antibodies ipilimumab and avelumab were co-injected in order to induce ADCC and CDC.